title: Lymphocyte-conditioned medium in combination with interleukin-2 effectively induces antitumour autoimmunity by adoptive transfer of short activated killer (SHAK) cells.
abstract: In this study, effective antitumour immunity was transferred by autologous short activated killer (SHAK) cells induced over four hours with lymphocyte conditioned medium (LCM) and recombinant interleukin-2 (rIL-2). Among eight patients with progressive metastatic renal cell carcinoma refractory to standard therapy, there were six objective tumour responses to SHAKs. Progression-free survival ranged from 0 to 8+ months, and overall survival ranged from 2 to 14+ months, with a median of 9+ months. Systemic toxicity of SHAKs was limited to flulike symptoms. Patient SHAKs provided a tumour-specific immunity, both cellular and humoral (expression and secretion of secondary cytokines, including IL-2, GM-CSF, INF-gamma and TNF-alpha), far superior to rIL-2 activated killer cells.
authors.affiliation: Division of Haematology and Oncology, MHH University Medical Center, Hannover, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Buer
authors.forename: R
authors.initials: R
authors.lastname: Hilse
authors.forename: I
authors.initials: I
authors.lastname: Dallmann
authors.forename: J
authors.initials: J
authors.lastname: Grosse
authors.forename: H
authors.initials: H
authors.lastname: Kirchner
authors.forename: U
authors.initials: U
authors.lastname: Zorn
authors.forename: E L
authors.initials: EL
authors.lastname: Hänninen
authors.forename: A
authors.initials: A
authors.lastname: Franzke
authors.forename: S
authors.initials: S
authors.lastname: Duensing
authors.forename: H
authors.initials: H
authors.lastname: Poliwoda
mesh_terms: D019264:Adoptive Transfer / Q000009:adverse effects; D002292:Carcinoma, Renal Cell / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D002478:Cells, Cultured; D017077:Culture Media, Conditioned; D016207:Cytokines / Q000096:biosynthesis*; D003602:Cytotoxicity, Immunologic; D018572:Disease-Free Survival; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D007694:Killer Cells, Natural / Q000637:transplantation*; D017710:Lymphocyte Transfusion; D008214:Lymphocytes / Q000166:cytology / Q000276:immunology*; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000096:biosynthesis; D011994:Recombinant Proteins / Q000627:therapeutic use; D015996:Survival Rate; D014158:Transcription, Genetic; D014182:Transplantation, Autologous
chemical_list: D017077:Culture Media, Conditioned; D016207:Cytokines; D007376:Interleukin-2; D012333:RNA, Messenger; D011994:Recombinant Proteins